Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Enanta Pharmaceuticals Inc (ENTA)
Price$14.08Cached quote
Net income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M | $122.5M | $205.2M | $206.6M | $102.8M | $88.3M | $160.9M | $47.7M | $32.1M | $41.7M | $41.9M |
| Research & development | $106.7M | $131.5M | $163.5M | $164.5M | $174.1M | $136.8M | $142.2M | $94.9M | $57.5M | $40.5M | $23.2M | $18.7M | $16.8M | $15.1M | $11.5M |
| Operating expenses | $150.7M | $189.3M | $216.4M | $210.0M | $206.6M | $164.1M | $168.5M | $118.3M | $78.2M | $57.4M | $36.7M | $28.8M | $23.0M | $20.4M | $16.6M |
| Operating income | −$85.3M | −$121.7M | −$137.2M | −$123.8M | −$109.6M | −$41.6M | $36.7M | $88.3M | $24.6M | $30.8M | $124.1M | $19.0M | $9.0M | $21.3M | $25.3M |
| Operating margin | −130.65% | −179.92% | −173.23% | −143.74% | −112.88% | −34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.05% | 60.41% |
| EBITDA | −$80.8M | −$119.4M | −$134.8M | −$120.9M | −$106.2M | −$38.0M | $40.0M | $90.8M | $26.8M | $32.5M | $124.8M | $19.3M | $9.3M | $21.5M | $25.8M |
| EBITDA margin | −123.63% | −176.47% | −170.24% | −140.29% | −109.44% | −31.02% | 19.49% | 43.97% | 26.02% | 36.82% | 77.57% | 40.50% | 28.86% | 51.46% | 61.60% |
| Net income | −$81.9M | −$116.0M | −$133.8M | −$121.8M | −$79.0M | −$36.2M | $46.4M | $72.0M | $17.7M | $21.7M | $79.0M | $34.4M | $9.6M | $21.4M | $23.3M |
| Net profit margin | −125.36% | −171.58% | −168.95% | −141.31% | −81.38% | −29.53% | 22.60% | 34.82% | 17.23% | 24.55% | 49.10% | 72.14% | 30.03% | 51.31% | 55.66% |
| Basic EPSper basic share | -$3.84 | -$5.48 | -$6.38 | -$5.91 | -$3.92 | -$1.81 | $2.37 | $3.74 | $0.93 | $1.14 | $4.23 | $1.88 | -$0.67 | $1.26 | $1.40 |
| Diluted EPSper diluted share | -$3.84 | -$5.48 | -$6.38 | -$5.91 | -$3.92 | -$1.81 | $2.21 | $3.48 | $0.91 | $1.13 | $4.09 | $1.80 | -$0.67 | $1.13 | $1.32 |
Owners
Reported shareholders
12.55%of listed shares
Jupiter Topco LLC3.65M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Jupiter Topco LLC | 12.55%3.65M shares |
BlackRock, Inc. | 11.14%3.24M shares |
Krensavage Asset Management, LLC | 9.84%2.87M shares |
FARALLON CAPITAL MANAGEMENT, L.L.C. | 8.30%2.42M shares |
Deep Track Capital, LP | 4.96%1.44M shares |
ADAR1 Capital Management, LLC | 4.62%1.34M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.16%1.21M shares |
Spruce Street Capital LP | 3.74%1.09M shares |
ACADIAN ASSET MANAGEMENT LLC | 3.70%1.08M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.47%1.01M shares |
Luly Jay R. | ≈2.99%871.87K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.67%776.63K shares |
MILLENNIUM MANAGEMENT LLC | 2.21%643.97K shares |
STATE STREET CORP | 1.98%576.12K shares |
RENAISSANCE TECHNOLOGIES LLC | 1.91%557.6K shares |
Hillsdale Investment Management Inc. | 1.61%468K shares |
GOLDMAN SACHS GROUP INC | 1.60%464.65K shares |
Or Yat Sun | ≈1.29%374.85K shares |
MORGAN STANLEY | 1.08%315.73K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.03%301.15K shares |
Percentages use 29.12M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 5, 2025Form 4 | Capps Kathleen S.See Remarks | SellCommon Stock | 323 | $14.23 | $4.6K | 8.4K |
| Dec 5, 2025Form 4 | Trout Harry R. IIISee Remarks | SellCommon Stock | 542 | $14.23 | $7.7K | 16.3K |
| Dec 5, 2025Form 4 | Rottinghaus Scott T.Chief Medical Officer | SellCommon Stock | 798 | $14.23 | $11.4K | 21.8K |
| Dec 5, 2025Form 4 | Luu BrendanChief Business Officer | SellCommon Stock | 1.4K | $14.23 | $19.8K | 38.3K |
| Dec 5, 2025Form 4 | Kieffer Tara LynnChief Product Strategy Officer | SellCommon Stock | 2.1K | $14.23 | $30.0K | 30.6K |